Don't Buy Cameco Before Checking Its Fundamentals!

By Susan Ramirez • Tuesday, December 19 17:07 • Permanent Link

Cameco sank -5.5% today, compared to the S&P 500's day change of 1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Cameco has moved 112.9% over the last year, and the S&P 500 logged a change of 24.0%
CCJ has an average analyst rating of buy and is -13.87% away from its mean target price of $50.82 per share
Its trailing earnings per share (EPS) is $0.45
Cameco has a trailing 12 month Price to Earnings (P/E) ratio of 97.3 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $1.1 and its forward P/E ratio is 39.8
The company has a Price to Book (P/B) ratio of 3.11 in contrast to the S&P 500's average ratio of 2.95
Cameco is part of the Basic Materials sector, which has an average P/E ratio of 16.53 and an average P/B of 2.07
The company has a free cash flow of $250.47 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Cameco Corporation provides uranium for the generation of electricity. It operates through two segments, Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, and milling, purchase, and sale of uranium concentrate. The Fuel Services segment engages in the refining, conversion, and fabrication of uranium concentrate, as well as the purchase and sale of conversion services. This segment also produces fuel bundles and assemblies, and zirconium-based reactor components for CANDU reactors. The company offers nuclear fuel processing services. It sells its uranium and fuel services to nuclear utilities in the Americas, Europe, and Asia. Cameco Corporation was incorporated in 1987 and is headquartered in Saskatoon, Canada.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.